At the "China Pharmaceutical Innovation and Investment Conference", after the release of the Phase I clinical data (including the involved tumor spectrum and treatment trends) of the CHA injection developed by  Jiuzhang Biotech, Nature magazine conducted exclusive interviews with Mr. Zhang Jie, the inventor, Professor Chen Xiaoguang from the Institute of Materia Medica of the Chinese Academy of Medical Sciences who is in charge of the research on the anti-tumor mechanism, and Professor Li Wenbin from the Department of Glioma at Beijing Shijitan Hospital who is the main person in charge of the glioma clinical trial.

Li Wenbin (the first from the left), Zhang Jie (the second from the left), and Chen Xiaoguang (the third from the left) received an exclusive interview from the reporter of Nature magazine.

According to the questions from the reporter of Nature magazine in the exclusive interview, they introduced the research and development process of the CHA preparation, its pharmacological properties, the toxicity, tolerance, pharmacokinetics in the clinical research, the treatment trend for malignant tumors, and the future development direction. As a globally first-invented (with independent intellectual property rights) natural small-molecule drug, it has a wide range of pharmacological activities. The research on the treatment mechanism shows that the CHA preparation has shown a good response effect on a variety of diseases, including malignant tumors and autoimmune diseases (such as psoriatic erythroderma and systemic lupus erythematosus); it acts on multiple targets and through multiple pathways. It is a broad-spectrum drug with low toxicity and low irritation.

A total of 85 international and domestic invention patents and 1 utility model patent have been applied for, focusing on disease treatment, CHA-related derivatives, core processes, and new dosage forms. 20 patents have been authorized. The other 66 patents are all in the normal examination process.

Yingying Zhou, the Custom Publishing Editor of Nature Research in Greater China, and Steve Qian, the Account Manager of Nature magazine in Greater China, demonstrated profound pharmaceutical expertise and extensive scientific knowledge when asking questions.